Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance

  • Nahta R
N/ACitations
Citations of this article
25Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Resistance to the HER2-targeted antibody trastuzumab is a major clinical concern in the treatment of HER2-overexpressing metastatic breast cancer. Increased expression or signaling of the insulin-like growth factor-I receptor (IGF-IR) has been reported in a subset of cell lines and clinical samples derived from trastuzumab-resistant breast cancers. Genetic and pharmacologic inhibition of IGF-IR signaling has been shown to improve response to trastuzumab in trastuzumab-naïve and trastuzumab-resistant models. In this paper, we will discuss the role of IGF-IR signaling in trastuzumab resistance. Further, we will discuss cotargeting IGF-IR and HER2 as a potential therapeutic strategy for HER2-over-expressing breast cancers that have progressed on trastuzumab treatment.

Cite

CITATION STYLE

APA

Nahta, R. (2012). Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance. Chemotherapy Research and Practice, 2012, 1–7. https://doi.org/10.1155/2012/648965

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free